Get the Stockscreener App
6.66
5.05%
0.32
After Hours:
6.79
0.13
+1.95%
Actuate Therapeutics Inc stock is traded at $6.66, with a volume of 94,392.
It is up +5.05% in the last 24 hours and down -9.39% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$6.34
Open:
$6.63
24h Volume:
94,392
Relative Volume:
1.21
Market Cap:
$154.80M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.63%
1M Performance:
-9.39%
6M Performance:
+1.06%
1Y Performance:
-19.57%
1-Day Range:
$6.42
$6.83
1-Week Range:
$5.7501
$6.83
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
6.66 | 147.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results - Investing.com Nigeria
Actuate Therapeutics stock rises on positive pediatric cancer trial data By Investing.com - Investing.com Australia
Actuate Therapeutics stock rises on positive pediatric cancer trial data - Investing.com
Actuate Therapeutics Announces Positive Patient Outcomes - GlobeNewswire
Analyst Downgrade: Is Actuate Therapeutics Inc stock supported by innovation pipelineTrade Performance Summary & Daily Profit Focused Stock Screening - moha.gov.vn
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher – Here’s What Happened - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% HigherHere's What Happened - MarketBeat
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
Actuate Therapeutics, Inc. (ACTU) upgraded to buy: What does it mean for the stock? - MSN
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? - sharewise.com
Can Actuate Therapeutics Inc stock maintain growth trajectoryJuly 2025 Drop Watch & Consistent Income Trade Ideas - moha.gov.vn
Why Actuate Therapeutics Inc. stock remains on buy lists2025 Top Decliners & Real-Time Price Movement Reports - Улправда
What risks investors should watch in Actuate Therapeutics Inc. stockJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analystsWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
How Actuate Therapeutics Inc. stock reacts to oil pricesJuly 2025 WrapUp & Daily Profit Focused Screening - DonanımHaber
How sustainable is Actuate Therapeutics Inc. stock dividend payoutBull Run & AI Forecasted Entry/Exit Points - DonanımHaber
Can Actuate Therapeutics Inc. stock maintain growth trajectory2025 Technical Patterns & Verified Technical Trade Signals - DonanımHaber
What Wall Street predicts for Actuate Therapeutics Inc. stock priceJuly 2025 Earnings & Low Volatility Stock Recommendations - Улправда
Actuate to present phase 2 pancreatic cancer study data at ASCO GI By Investing.com - Investing.com South Africa
Fed Meeting: Is Actuate Therapeutics Inc. stock a buy for dividend growthStop Loss & Free Community Consensus Stock Picks - Улправда
Is Actuate Therapeutics Inc. stock a buy for dividend growthQuarterly Trade Review & Consistent Income Trade Recommendations - Улправда
Actuate to present phase 2 pancreatic cancer study data at ASCO GI - Investing.com Nigeria
Actuate Therapeutics Announces Presentation of Phase 2 Study Data on Elraglusib in Metastatic Pancreatic Cancer at ASCO GI Cancers Symposium 2026 - Quiver Quantitative
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - The Manila Times
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer - GlobeNewswire
Actuate reports promising results for elraglusib in salivary cancer By Investing.com - Investing.com Australia
Actuate reports promising results for elraglusib in salivary cancer - Investing.com
Actuate Therapeutics Announces Promising Phase II Study Results for Elraglusib in Advanced Salivary Gland Cancer - Quiver Quantitative
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - GlobeNewswire
Actuate Therapeutics Reports Positive Phase II Data In Salivary Gland Cancers - Nasdaq
Certain Options of Actuate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU - MarketBeat
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - MSN
Published on: 2025-12-07 08:30:16 - BỘ NỘI VỤ
Will Actuate Therapeutics Inc. stock see PE expansionInsider Selling & Daily Chart Pattern Signal Reports - Newser
Why Actuate Therapeutics Inc. stock is a must watch in 2025Forecast Cut & AI Based Buy and Sell Signals - Newser
Actuate Therapeutics enters $100 million at-the-market sales agreement - Investing.com
Actuate Therapeutics Signs $100M Sales Agreement - TipRanks
Actuate Therapeutics Inc enters at the market issuance sales agreement with B. Riley and Craig-HallumSEC filing - marketscreener.com
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Zacks Investment Research
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st
BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU - Defense World
What analysts say about Actuate Therapeutics Inc stockTrade Execution Strategies & Daily Tips From Top Market Analysts - earlytimes.in
Will Upside Catalysts Materialize for Prime Industries Limited in YEARHigh Frequency Trading Trends & Free Unlock Rapid Growth Potential - earlytimes.in
HC Wainwright Has Bullish Estimate for ACTU FY2025 Earnings - Defense World
Why Actuate Therapeutics Inc. stock is in analyst buy zoneEarnings Trend Report & Verified Entry Point Signals - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Given "Buy" Rating at HC Wainwright - MarketBeat
Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating - TipRanks
HC Wainwright & Co. Reiterates Actuate Therapeutics (ACTU) Buy Recommendation - Nasdaq
How Actuate Therapeutics Inc. stock compares to market leadersEarnings Overview Report & Expert Approved Momentum Ideas - newser.com
Using R and stats models for Actuate Therapeutics Inc. forecastingRate Hike & Fast Gaining Stock Reports - newser.com
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):